Price$1.50+0.12 (+8.70%)
01:30 PM07:45 PM
News · 26 weeks32-29%
2025-12-142026-06-07
Mix1490d
- SEC Filings8(57%)
- Other4(29%)
- Earnings1(7%)
- Insider1(7%)
Latest news
25 items- INSIDERChief Technical Officer Kasraian Kasra sold $1,739 worth of shares (1,233 units at $1.41) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 50,074 units (SEC Form 4) (withholding tax)4 - PepGen Inc. (0001835597) (Issuer)
- SECSEC Form EFFECT filed by PepGen Inc.EFFECT - PepGen Inc. (0001835597) (Filer)
- SECPepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 ProgramPepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic dystrophy type 1 (DM1).
- SECSEC Form S-3 filed by PepGen Inc.S-3 - PepGen Inc. (0001835597) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)
- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- SECSEC Form 10-Q filed by PepGen Inc.10-Q - PepGen Inc. (0001835597) (Filer)
- PRPepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as of March 31, 2026, sufficient to fund operations through FREEDOM2 12.5 mg/kg MAD readout and into 2H 2027 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights f
- SECSEC Form DEFA14A filed by PepGen Inc.DEFA14A - PepGen Inc. (0001835597) (Filer)
- SECSEC Form DEF 14A filed by PepGen Inc.DEF 14A - PepGen Inc. (0001835597) (Filer)
- SECPepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing correction of 22.9% (n=5) – – Promising trends observed in vHOT in the PGN-EDODM1 treated group – – Company on track to report clinical data from 10 mg/kg multiple dose cohort in 2H 2026 with sufficient cash expected to fund operations into 2H 2027– – Conference call scheduled today at 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next genera
- SECSEC Form SCHEDULE 13G filed by PepGen Inc.SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)
- INSIDEREVP, Head of R&D Streck Paul sold $11,709 worth of shares (1,879 units at $6.23), decreasing direct ownership by 2% to 76,226 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERChief Financial Officer Donnelly Noel sold $12,988 worth of shares (2,084 units at $6.23), decreasing direct ownership by 2% to 111,603 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERPresident and CEO Mcarthur James G sold $32,876 worth of shares (5,275 units at $6.23), decreasing direct ownership by 2% to 296,326 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- SECPepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- SECSEC Form S-8 filed by PepGen Inc.S-8 - PepGen Inc. (0001835597) (Filer)
- SECSEC Form 10-K filed by PepGen Inc.10-K - PepGen Inc. (0001835597) (Filer)
- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Regulatory Updates on FREEDOM2- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada - - PepGen reiterates guidance for reporting data from the FREEDOM2 5 mg/kg cohort in Q1 2026 and from the 10 mg/kg cohort in 2H 2026 - PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory updates related to the FREEDOM2 trial. The U.S. Food and Drug Administrati
- PRPepGen to Participate in the Leerink Global Healthcare ConferencePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentatio
- INSIDERChief Business & Legal Officer Vittiglio Joseph was granted 30,717 shares, increasing direct ownership by 88% to 65,717 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
PEPG FAQ
7 questionsWhat does PepGen Inc. do?
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is...Where does PEPG stock trade?
PepGen Inc. (PEPG) is listed on NASDAQ.What sector and industry is PEPG in?
PepGen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PepGen Inc. go public?
PepGen Inc. (PEPG) completed its IPO in 2022.What are analysts saying about PEPG?
PepGen Inc. has had 4 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $600.00 price target on 2025-09-09.What companies are similar to PEPG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PEPG side-by-side with any of them on Quantisnow.How can I track PEPG on Quantisnow?
Quantisnow aggregates PepGen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PEPG to receive live email and push alerts on every new disclosure.